Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes
Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is the hepatic manifestation of metabolic syndrome. Hepatic lipotoxicity and inflammation are two key factors driving progression of steatosis to metabolic dysfunction-associated steatohepatitis (MASH). The presence of MASH in...
Saved in:
| Main Authors: | Adeyinka Taiwo, Himani Thakkar, J. Alan Maschek, James Cox, Scott A. Summers, Diana Jalal, Ayotunde Dokun, William I. Sivitz, Bhagirath Chaurasia |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-15778-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metabolite perturbations in type 1 diabetes associated with metabolic dysfunction-associated steatotic liver disease
by: Adeyinka Taiwo, et al.
Published: (2025-06-01) -
Relative fat mass and risk of metabolic dysfunction associated steatotic liver disease and severe hepatic steatosis in U.S. adults: analysis of NHANES 2017–2020 data
by: Jianjun Wang, et al.
Published: (2025-05-01) -
The diagnostic value of MRI-PDFF in hepatic steatosis of patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
by: Yue-Xia Zhang, et al.
Published: (2025-07-01) -
Metabolic dysfunction‐associated steatotic liver disease: A superior predictor for incident type 2 diabetes over traditional criteria – NAGALA study
by: Kimiko Sakai, et al.
Published: (2024-12-01) -
Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
by: Toru Nakamura, et al.
Published: (2025-03-01)